Effect of Rowachol on Prevention of Postcholecystectomy Syndrome

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually manifested by the presence of abdominal symptoms following gallbladder removal. The pathogenesis of PCS has not been identified; therefore there is no consensus of medical treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients with cholesterol gallstones, and to promote biliary lipid secretion.

The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS and symptoms change after laparoscopic cholecystectomy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: DongGuk University
• Collaborator: Pharmbio Korea Co., Ltd.

Criteria

Inclusion Criteria:

• Patients with pathologic diseases scheduled for laparoscopic cholecystectomy

Exclusion Criteria:

• Current immunosuppressive therapy

• Chemotherapy within 4 weeks before operation

• Radiotherapy completed longer than 4 weeks before operation

• Inability to follow the instructions given by the investigator

• Severe psychiatric or neurologic diseases

• Drug- and/or alcohol-abuse according to local standards

• Participation in another intervention-trial with interference of a primary or secondary endpoint of this study

• Lack of compliance

• Lack of informed consent